Skip to main content
  • Tweet
  • Share on Facebook
  • Share on Google +1
  • Share via Email
  • Contact
  • Glossary
  • Subscribe
  • Search

PATH's Malaria Vaccine Initiative

Accelerating Malaria Vaccine Development

  • About us
    • Our leadership team
    • Donors
    • Contact us
  • Malaria and vaccines
    • Need for a vaccine
    • RTS,S
    • Malaria vaccine roadmap
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Vaccine development
      • Our research and development strategy
      • Life cycle of the malaria parasite
      • Preferred product characteristics
    • Evaluation technologies
    • Access
      • Global policy and regulatory pathways
        • Regulatory decisions and prequalifications
        • Policy
      • Preparing for malaria vaccine decisions
        • The decision-making framework tool for malaria vaccines
        • Decision-making framework
          • Economic analysis
          • Public health impact analysis
          • Sociocultural research
      • Financing
        • Gavi, the Vaccine Alliance
        • Other fincancing mechanisms
  • Projects
    • Search vaccine projects
    • Evaluation technology projects
    • MVI Portfolio
    • Past projects
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Presentations
    • Videos
    • Reports
  • News and events
    • Press releases
    • Perspectives
    • Malaria vaccine news
    • Events
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Past advocacy fellows
      • Tools for advocates
    • Propose a project
  • About us
    • Our leadership team
    • Donors
    • Contact us
  • Malaria and vaccines
    • Need for a vaccine
    • RTS,S
    • Malaria vaccine roadmap
    • Next-generation vaccines
      • Preventing transmission
      • Preventing infection
    • Vaccine development
      • Our research and development strategy
      • Life cycle of the malaria parasite
      • Preferred product characteristics
    • Evaluation technologies
    • Access
      • Global policy and regulatory pathways
      • Preparing for malaria vaccine decisions
      • Financing
  • Projects
    • Search vaccine projects
    • Evaluation technology projects
    • MVI Portfolio
    • Past projects
  • Resources
    • Search all resources
    • Fact sheets
    • Journal articles
    • Presentations
    • Videos
    • Reports
  • News and events
    • Press releases
    • Perspectives
    • Malaria vaccine news
    • Events
  • Work with us
    • RFPs
    • Advocacy
      • Malaria Vaccine Advocacy Fellowship
      • Past advocacy fellows
      • Tools for advocates
    • Propose a project
  • Home
  • Home
A child sits with his mother

Two families reflect on their malaria vaccine journey

Catching up with the first children to receive the RTS,S malaria vaccine in Malawi, one year later.

Kenya strengthens fight against malaria with new vaccine

 The world's first malaria vaccine is now available in certain areas of Kenya, offering an additional way to protect young children from this disease, which is a top 10 cause of illness and death, and a leading killer of children under the age of five....

Research for implementation: Challenges of tracking funding flows highlighted in new report

Pilot survey of funders reveals challenges of tracking money; case studies show potential impact of this research on uptake and usability of drugs, diagnostics, vector control products, and vaccines. Read more...

We’re ready to beat malaria. Are you?

Put your knowledge to the test with a three-question quiz. Ready to begin?

Home

  • MVI Portfolio

    We strategically use our resources to support and advance a range of vaccine approaches that target both humoral and cellular immunity. 
    Explore
  • Evaluation technology projects

    We partner to develop and optimize new assays and challenge models and support reference and service laboratories.
    Explore
  • RTS,S

    RTS,S/AS01 (RTS,S) is the world’s first malaria vaccine shown to provide partial protection against malaria in young children.
    Explore

Latest

Milestone study identifies immune markers that may help predict success of vaccination with RTS,S/AS01 malaria vaccine
Press release
22 Jul 2020
PATH receives new five-year contract from USAID for malaria vaccine research and development
Press release
7 Jul 2020
A child sits with his mother Two families reflect on their malaria vaccine journey
Feature
23 Apr 2020
PATH continues exciting partnership with the GHIT Fund to develop a next-generation malaria vaccine
Press release
3 Apr 2020
Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein
Journal article
17 Mar 2020
RTS,S Malaria Vaccine: 2019 Partnership Award Honoree
Video
4 Dec 2019
PATH and partners receive award for development of world’s first malaria vaccine
Press release
14 Nov 2019
RTS,S malaria vaccine frequently asked questions (FAQs)
Fact sheet
17 Sep 2019
The RTS,S malaria vaccine
Fact sheet
17 Sep 2019
Pictured here with his mother, Elian Koech was the first child to receive the vaccine in Kenya. Kenya joins Malawi and Ghana to roll out the world’s first malaria vaccine
Press release
13 Sep 2019
Elian Koech was the first child to receive the malaria vaccine today in Kenya. Kenya strengthens fight against malaria with new vaccine
Feature
13 Sep 2019
Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers
Journal article
15 Aug 2019
  • Need for a vaccine

    A vaccine could help to close the gap left by other malaria control interventions.
  • Malaria vaccine roadmap

    The roadmap outlines a path for accelerating the development of malaria vaccines.
  • RTS,S

    RTS,S/AS01 (RTS,S) is the world’s first malaria vaccine shown to provide partial protection against...
  • Next-generation vaccines

    The next generation of malaria vaccines would aim to reduce transmission of the parasite.

Twitter @MalariaVaccine

A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking… https://t.co/bUxi9sBsSU
22 Jan 2021
RT @james_dunlap: 🇰🇪🇲🇼🇬🇭 "Kenya, Malawi, and Ghana have immunized nearly half a million children with the malaria vaccine over the la… https://t.co/eZkYssoxbq
19 Jan 2021
RT @FightingMalaria: We are calling for applicants to our Dr Sylvia Meek scholarship for Entomology in South Africa in partnership with… https://t.co/UOlutYCmCI
11 Jan 2021
RT @GHTCoalition: Advancing R&D for new health tools is an essential part of the solution to the world’s greatest #globalhealth chall… https://t.co/GHWQmyedX0
7 Jan 2021
RT @PATHtweets: “I think it's challenged everybody to say: ‘Look at what's actually possible.’” PATH's Ashley Birkett, Director… https://t.co/dSCNTtSIr3
4 Jan 2021
RT @NobelPrize: On 18 December 1897 Ronald Ross published his paper linking mosquitos and malaria transmission, that he had origina… https://t.co/wXVvpWvP8i
18 Dec 2020
Bloodsuckers – How malaria has shaped humanity https://t.co/HNqtv301gf
16 Dec 2020
RT @MESAmalaria: 📢 You still don't know what is #MESA Track? Here a short video to find out about our open and living #database of… https://t.co/l0j9aE3vjn
14 Dec 2020
RT @GHTCoalition: Our new report finds the #globalhealth #research infrastructure—a key force in accelerating advances against… https://t.co/9VHIWpIryC
11 Dec 2020
RT @FightingMalaria: The #COVID19 vaccine is a powerful reminder of how quickly safe and affordable vaccines can be developed when suffi… https://t.co/EJQodc9UpE
10 Dec 2020
RT @GHTCoalition: Check out our new resource which unpacks the complex web of multilateral organizations 🏛️🌐 and breaks down how each… https://t.co/LyiSkAsh6M
8 Dec 2020
“I think it's challenged everybody to say: Look at what's actually possible.” PATH's Ashley Birkett, Director… https://t.co/rKztgI93Qi
7 Dec 2020

PATH Washington DC

455 Massachusetts Avenue NW, Suite 1000

Washington, DC 20001 | USA 

Tel: 202.822.0033

Fax: 202.457.1466

Email: mvi_info [at] path.org

PATH Headquarters

2201 Westlake Avenue, Suite 200

Seattle, WA 98121 | USA 

Tel: 206.285.3500

Fax: 206.285.6619

Email: info [at] path.org

Website: www.path.org

Follow us

Mail
Twitter
  • Privacy policy
  • Copyright policy
  • Terms of use
© 2021 PATH
Website by Manta Ray Media